Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 10;11:42. doi: 10.1186/s13195-019-0498-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — Subchronic intravenous treatment of APP23 mice with human recombinant ApoJ (h-rApoJ). a Schematic timeline representing the experimental design of the study based on the subchronic administration of APP23 mice with rHDL-rApoJ nanodiscs, free rApoJ or saline. b Immunodetection (anti-h-ApoJ) of treatment samples before being intravenously infused. c Plasmatic levels of h-ApoJ in treated mice 30 min after the last administration detected by ELISA (N = 7/group). d Levels of h-ApoJ in brain homogenates from treated mice detected by ELISA (N = 7/group). e Immunofluorescent detection of h-ApoJ in paraffin-embedded brain sections. **p < 0.01; ***p < 0.001